Therefore, in this study, we genetically manipulated an oncolytic adenovirus designated SG635‐SF to express an engineered SIRPα and IgG1 Fc fusion protein and investigated its therapeutic effect against CD47‐high‐expressing ovarian cancer cells both in vitro and in vivo. The gene discussed is CD47; the disease is ovarian cancer.